Bristol Myers Squibb's Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer
CompanyDrug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer

Yifan Pharma Secures NMPA Approval for Generic Sedapain
CompanyDrug

Yifan Pharma Secures NMPA Approval for Generic Sedapain

Yunnan Baiyao's INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
CompanyDrug

Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer

Shanghai Kehua Bioengineering Launches Xi'an Medical Complex Project
CompanyDeals

Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project

HuidaGene's hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
CompanyDeals

HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes
Policy / Regulatory

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes

Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
CompanyDrug

Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU

Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock
CompanyDeals

Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock

Daiichi Sankyo and AstraZeneca's Datroway Approved in EU for Breast Cancer
CompanyDrug

Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China
CompanyDeals

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales
Company

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales

Winsunny Pharma's FY101 Gains NMPA Clinical Approval for Hyperlipidemia
CompanyDrug

Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia